BioCryst Pharmaceuticals, Inc.

Equities

BCRX

US09058V1035

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 10:56:12 2026-01-22 am EST			5-day change	1st Jan Change
6.800 ^USD	+1.19%		-4.72%	-12.41%

Jan. 21	Astria Therapeutics Shareholders Greenlight Acquisition by BioCryst Pharmaceuticals	MT
Jan. 12	Biocryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2026	CI

BioCryst Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025

Published on 11/03/2025 at 09:05 am EST - Modified on 11/03/2025 at 10:22 am EST

S&P Capital IQ

BIOCRYST PHARMACEUTICALS, INC.

+1.19%

BioCryst Pharmaceuticals, Inc. reported earnings results for the third quarter and nine months ended September 30, 2025. For the third quarter, the company reported revenue was USD 159.4 million compared to USD 117.09 million a year ago. Net income was USD 12.9 million compared to net loss of USD 14.03 million a year ago. Basic earnings per share from continuing operations was USD 0.06 compared to basic loss per share from continuing operations of USD 0.07 a year ago. Diluted earnings per share from continuing operations was USD 0.06 compared to diluted loss per share from continuing operations of USD 0.07 a year ago.
For the nine months, revenue was USD 468.28 million compared to USD 319.18 million a year ago. Net income was USD 18.02 million compared to net loss of USD 62.09 million a year ago. Basic earnings per share from continuing operations was USD 0.09 compared to basic loss per share from continuing operations of USD 0.3 a year ago. Diluted earnings per share from continuing operations was USD 0.08 compared to diluted loss per share from continuing operations of USD 0.3 a year ago.

Latest news about BioCryst Pharmaceuticals, Inc.

Jan. 21	Astria Therapeutics Shareholders Greenlight Acquisition by BioCryst Pharmaceuticals	MT
Jan. 12	Biocryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2026	CI
Jan. 12	BioCryst Pharmaceuticals, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 10:30 AM
Jan. 12	BioCryst Pharmaceuticals Expects Q4, 2025 Orladeyo Revenue to Increase	MT
Jan. 12	(BCRX) BioCryst Expects 2026 Revenue Range $635M to $660M, vs. FactSet Est of $660.5M	MT
Jan. 08	Praxis Precision Medicines, Inc. Announces Management Changes	CI
Jan. 08	RBC Cuts Price Target on BioCryst Pharmaceuticals to $14 From $15, Keeps Outperform Rating	MT
Dec. 30	BioCryst Pharmaceuticals Face Numerous Important Catalysts in 2026, Wedbush Says	MT
Dec. 12	Sector Update: Health Care Stocks Edge Higher Premarket Friday	MT
Dec. 12	Exchange-Traded Funds Lower, Equity Futures Mixed Pre-Bell Friday as Broadcom Results Deepen Fears	MT
Dec. 12	Biocryst Pharmaceuticals, Inc. Announces Fda Approval of Orladeyo® (Berotralstat) Oral Pellets, First and Only Oral Prophylactic Treatment for Patients with Hae Aged 2 to <12 Years	CI
Dec. 12	BioCryst Receives FDA Approval for Orladeyo For Young Hereditary Angioedema Patients	MT
Dec. 12	BioCryst Gets FDA OK for Pediatric Use of Orladeyo	DJ
Dec. 12	FDA approves BioCryst's oral pellet version of swelling disorder drug for children	RE
Dec. 12	FDA expands approval of BioCryst's rare disease drug for use in young children	RE
Dec. 11	Biocryst Pharmaceuticals, Inc. Announces Retirement of Nancy J. Hutson, Ph.D. and Election of Vincent J. Milano as Next Chair of the Board	CI
Dec. 04	Biocryst reports inducement grants under Nasdaq Listing Rule 5635(c)(4)	RE
Dec. 03	Biocryst receives early termination of Hart-Scott-Rodino waiting period for Astria acquisition	RE
Dec. 03	BioCryst Pharmaceuticals-Astria Deal Clears Regulatory Hurdle	MT
Nov. 24	BioCryst Pharmaceuticals, Inc. Presents at Jefferies London Healthcare Conference 2025, Nov-19-2025 05:00 PM
Nov. 06	BioCryst Presents New Data at ACAAI Highlighting Burden of HAE on Pediatric Patients and Caregivers and Sustained Reduction of Attacks in Children Treated with One Year of ORLADEYO	CI
Nov. 03	BioCryst Pharmaceuticals, Inc. Appoints Ron Dullinger as Chief Commercial Officer, Effective January 1, 2026	CI
Nov. 03	BioCryst Pharmaceuticals, Inc. Revises Earnings Guidance for the Full Year 2025	CI
Nov. 03	BioCryst Pharmaceuticals, Inc., Q3 2025 Earnings Call, Nov 03, 2025
Nov. 03	BioCryst Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI

Chart BioCryst Pharmaceuticals, Inc.

Duration

Period

BCRX: Dynamic Chart

Company Profile

BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on improving the lives of people living with complement-mediated and other rare diseases. The Company leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older.

Employees

580

Sector

Biotechnology & Medical Research

Calendar

Feb. 24 - Q4 2025 Earnings Release (Projected)

More about the company